Keywords: ودولیزومب; Inflammatory bowel disease; Vedolizumab; Postoperative outcomes;
مقالات ISI ودولیزومب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ودولیزومب; Crohn's disease; Ulcerative colitis; Inflammatory bowel disease; Vedolizumab; Surgery; Complications;
Keywords: ودولیزومب; Inflammatory bowel disease (IBD); acute interstitial nephritis (AIN); monoclonal antibody; vedolizumab; acute renal failure (ARF); acute kidney injury (AKI); ulcerative colitis; Crohn's disease; glucocorticoids; kidney biopsy; case report;
Keywords: ودولیزومب; Arthritis; Spondyloarthritis; Inflammatory bowel disease; Vedolizumab;
Keywords: ودولیزومب; IBD; CD; Prediction Model; Biomarker; AUC; area under the curve; CD; Crohn's disease; CDST; clinical decision support tool; CREM; clinical remission; CRP; C-reactive protein; CSF-REM; corticosteroid-free remission; MH; mucosal healing; TNFα; tumor necr
Keywords: ودولیزومب; Vedolizumab; Immunomodulator; Monotherapy; Combination therapy; Ulcerative colitis;
Keywords: ودولیزومب; Integrin; Vedolizumab; FOXP3; Helios; Stat; Crohn's disease; Treg; Th1; Th2; cTFH; IL-2, IL-6, IL-7, IL-21; IBD; inflammatory bowel disease; CD; Crohn's disease; MS; multiple sclerosis; Treg; regulatory T cell; tTreg; thymically-derived Treg; pTreg; perip
Keywords: ودولیزومب; Crohn's disease; Ulcerative colitis; Monoclonal antibody; Anti-TNF; Vedolizumab; Ustekinumab; Biologics;
Keywords: ودولیزومب; Enfermedad inflamatoria intestinal; Enfermedad de Crohn; Colitis ulcerosa; Tratamiento; Inmunosupresores; Anti-TNF; Biosimilar; Vedolizumab; Tofacitinib; Células madre; Trasplante fecal; Inflammatory bowel disease; Crohn disease; Ulcerative colitis; Trea
Keywords: ودولیزومب; Colitis ulcerosa; Vedolizumab; Enfermedad inflamatoria intestinal; Integrinas; Moléculas de adhesión; Ulcerative colitis; Vedolizumab; Inflammatory bowel disease; Integrins; Adhesion molecules;
Keywords: ودولیزومب; Crohn's Disease; Inflammatory Bowel Disease; Ulcerative Colitis; Vedolizumab
Keywords: ودولیزومب; Inflammatory bowel disease; Crohn's disease; Ulcerative colitis; Biological agents; Vedolizumab; Golimumab; BiosimilarEnfermedad inflamatoria intestinal; Enfermedad de Crohn; Colitis ulcerosa; Biológicos; Vedolizumab; Golimumab; Biosimilar
Keywords: ودولیزومب; Ulcerative Colitis; 5-Aminosalicylate; Corticosteroid; Thiopurine; Anti-Tumor Necrosis Factor; Vedolizumab; Probiotics; ADA; antidrug antibodies; CAG; Canadian Association of Gastroenterology; CI; confidence interval; FMT; fecal microbial transplant; GR
Keywords: ودولیزومب; ADA; adalimumab; CD; Crohn disease; CDAI; Crohn's Disease Activity Index; CrI; credible interval; CZP; certolizumab pegol; HR; hazard ratio; IBD; inflammatory bowel disease; IFX; infliximab; IL-12/23; interleukin 12/23; NAT; natalizumab; OR; odds ratio;
Keywords: ودولیزومب; Entyvio; infusion; liver injury; progressive multifocal leukoencephalopathy; protocol; safety; vedolizumab
Effectiveness of vedolizumab for Crohn's disease with spondyloarthritis in fail with two TNF blocking agents
Keywords: ودولیزومب; Vedolizumab; Spondyloarthritis; Crohn's disease; Nephrotic syndrom;
Ustekinumab in the management of Crohn's disease: Expert opinion
Keywords: ودولیزومب; Anti-tumor necrosis factor agents; Crohn's disease; Monoclonal antibodies; Ustekinumab; Vedolizumab;
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate rece
Keywords: ودولیزومب; Alefacept; Fingolimod; Infection; Ipilimumab; Natalizumab; Nivolumab; Pembrolizumab; Progressive multifocal leukoencephalopathy; Proteasome inhibitors; Vedolizumab;
Brief ArticlesTargeting Integrin α4β7 in Steroid-Refractory Intestinal Graft-versus-Host Disease
Keywords: ودولیزومب; Graft-versus-host disease; Stem cell transplant; Vedolizumab; Gut GVHD; Integrin; Steroid refractory;
Protocolo diagnóstico y terapéutico de un brote grave de colitis ulcerosa
Keywords: ودولیزومب; Esteroides; Colitis ulcerosa; Brote grave; Infliximab; Adalimumab; Golimumab; Vedolizumab; Steroids; Ulcerative colitis; Severe outbreak; Infliximab; Adalimumab; Golimumab; Vedolizumab;
Nuevas moléculas en el tratamiento de la enfermedad inflamatoria intestinal
Keywords: ودولیزومب; Enfermedad inflamatoria intestinal; Enfermedad de Crohn; Colitis ulcerosa; Biológicos; Vedolizumab; Golimumab; BiosimilarInflammatory bowel disease; Crohn's disease; Ulcerative colitis; Biological agents; Vedolizumab; Golimumab; Biosimilar
The Gut-Liver Axis in Primary Sclerosing Cholangitis
Keywords: ودولیزومب; Primary sclerosing cholangitis; Inflammatory bowel disease; Vedolizumab; Cholangiocarcinoma; Genetics; Microbiome; Pouchitis;
Associate editor: Graeme EisenhoferLeukocyte integrins: Role in leukocyte recruitment and as therapeutic targets in inflammatory disease
Keywords: ودولیزومب; Integrin; Leukocyte adhesion; Natalizumab; Efalizumab; Vedolizumab; Del-1; BBB; Blood-brain barrier; CCL; CC-chemokine ligand; CAMs; cell adhesion molecules; CNS; central nervous system; CD; Crohn's disease; CXCL; CXC-chemokine ligand; DCs; dendritic ce
Lymphocyte Homing Antagonists in the Treatment of Inflammatory Bowel Diseases
Keywords: ودولیزومب; Natalizumab; Vedolizumab; Etrolizumab; Integrins; Chemokine receptors; Inflammatory bowel disease; Ulcerative colitis; Crohn disease;
Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype
Keywords: ودولیزومب; Vedolizumab; Inflammatory bowel disease; Cerebrospinal fluid; Immune surveillance;